InnoCare Pharma, a commercial-stage biotech company, announced that the U.S. Food and Drug Administration has cleared the Investigational New Drug application for the Company’s B-cell lymphoma-2 inhibitor, ICP-248.
InnoCare Pharma, a commercial-stage biotech company, announced that the U.S. Food and Drug Administration has cleared the Investigational New Drug application for the Company’s B-cell lymphoma-2 inhibitor, ICP-248.